Good morning, or good afternoon depending on your time zone, and thank you for your participation today. I'd now like to call to order the 2021 Annual Meeting of Stockholders of Alnylam Pharmaceuticals, Inc, which is being held virtually via the Internet. I am Michael Bonney, Chair of the Board of Directors of the company. I would like to introduce the other directors who are with us today for this annual meeting: Dennis Ausiello, Olivier Brandicourt, Marsha Fanucci, Margaret Hamburg, John Maraganore, who is the company's Chief Executive Officer, Steve Paul, David Pyott, Colleen Reitan, Amy Schulman, and Phil Sharp, constituting all of the members of our board.
Also with us today are several members of the company's senior management and investor relations teams, including Yvonne Greenstreet, President and Chief Operating Officer, Akshay Vaishnaw, President, Research and Development, Pushkal Garg, Chief Medical Officer, Laurie Keating, Chief Legal Officer and Secretary, Jeff Poulton, Chief Financial Officer, Christine Lindenboom, Senior Vice President, Investor Relations, Mary Beth DeLena, Senior Vice President and Deputy General Counsel, and Josh Brodsky, Director, Investor Relations. Representatives of PricewaterhouseCoopers LLP, the company's independent auditors, including PwC partner Mark Barsanti, are also participating and will be available following the formal portion of the meeting to respond to appropriate questions from stockholders submitted online. On behalf of your board of directors and management, I welcome all stockholders in attendance today at our 2021 annual meeting. Clearly, the last 15 or so months is unprecedented in the experience of all who live and work on the planet today.
In addition to the terrible toll on human health and life that has been exacted by SARS-CoV-2, it has forced us all to live and work differently. The extraordinary job that John, the leadership of Alnylam, and importantly, all of our colleagues have done to both appropriately protect the health and safety of employees while simultaneously advancing the business in a mission-driven way warrants acknowledgment and deep thanks. Very early in this outbreak, Alnylam established itself as a leader within the life sciences sector on how best to respond. This response put the safety of our colleagues and neighbors first but did not shy away from figuring out how, in this brave new working environment, we could continue to advance the incredibly important work of the firm.
As we now begin to seriously work through how best to re-engage as more and more of society is vaccinated, I want to thank the Alnylam team, starting with John and throughout the ranks, for their dedication, thoughtfulness, and commitment to our patients and stockholders. My sincere thanks are also extended to all stockholders voting today, whether by proxy in advance of the meeting or online during the meeting. Thank you for your interest in the company's mission and business and future prospects. I will now turn the meeting over to Laurie Keating, the company's Chief Legal Officer, who will conduct the formal part of the annual meeting and serve as Secretary of this meeting as well. Laurie?
Thank you for those very gracious remarks, Mr. Bonney. Good morning, good afternoon, and welcome to all our stockholders participating online today. We will now begin the formal portion of the annual meeting. During the meeting, stockholders participating online may submit questions through the virtual meeting platform by typing your question into the Ask a Question field and clicking Submit. Questions pertinent to meeting matters will be answered following the formal portion of the meeting, subject to time constraints. Any questions pertinent to meeting matters that cannot be answered due to time constraints will be posted online and answered on Alnylam's website under the Investor section. Following the formal meeting this morning, Josh Brodsky, a Senior Director in Alnylam's Investor Relations Group, will present a brief company update and be available to answer any additional questions submitted online during his presentation.
As indicated in the Notice of Meeting and in the company's proxy statement that was made available on the Internet, the following matters have been proposed by the board for approval or ratification by the stockholders who were stockholders of record as of the record date: first, to elect four members to the Board of Directors to serve as Class II directors, each for a term of three years, second, to approve in a non-binding advisory, say-on- pay vote, the compensation of the company's named executive officers, and third, to ratify the appointment by the company's board of directors of PricewaterhouseCoopers LLP as the company's independent auditors for the current fiscal year ending December 31st, 2021. We will consider each item in turn in the same order that they appear in the Notice of Meeting.
The polls will open when the first matter is called to a vote and will remain open until I announce that the polls are closed. You may vote your shares during the meeting online through the virtual meeting platform. You will need the 16-digit control number included on your proxy card or voting instruction form. If you previously voted, that will not limit your right to vote online during the meeting through the virtual meeting platform, and your online vote will supersede the vote you submitted previously. No online votes, ballots, or proxies, or revocations of or changes to online votes, ballots, or proxies will be accepted after the polls are closed. I will announce the preliminary voting results on each matter following the tabulation of the voting.
I have received an affidavit from Broadridge Financial Solutions, the company's agent for distribution, certifying that the Notice of the Annual Meeting was sent to all stockholders of record as of March 29, 2021, and the proxy statement was made available on the internet as of April 2, 2021. This affidavit is available for inspection by any of our stockholders. I'd like to now introduce Mr. Louis Larson. Mr. Larson has been appointed to act as Inspector of Election and has taken the Inspector of Election oath. I'd like to ask Mr. Larson to state the number of shares present at this meeting. Mr. Larson?
Yes. There are present at this meeting in person or through representation by proxy 105,693,138 shares of common stock, representing approximately 91% of the outstanding shares of common stock of the company as of 10:30 A.M. this morning.
Thank you, Mr. Larson. Based on the number of shares reported as present at this meeting, I am happy to report that a quorum exists. Voting today is by proxy and virtual ballot. It is not necessary for stockholders to vote by virtual ballot if they have already submitted their proxy cards, unless they wish to change their vote. Virtual ballots are available for any stockholder who wishes to vote by virtual ballot or to change their vote. Stockholders may do so online through the virtual meeting platform. Your submission of a virtual ballot will revoke all prior proxies. Voting is now open for all matters to be presented. Voting shall be closed after we go through the proposals to be voted upon. I will now review the proposals.
Proposal 1: The first matter to be voted on is the election of four Class II directors, each for a term of three years. The nominees for election are Dr. Dennis Ausiello, Dr. Olivier Brandicourt, Ms. Marsha Fanucci, and Mr. David Pyott. Proposal 2: The second matter to be voted on is the non-binding advisory vote on executive compensation. Proposal 3: The third and final matter to be voted on is the ratification of the appointment of PricewaterhouseCoopers LLP as the company's independent auditors for the 2021 fiscal year. This concludes the business items on the agenda for this annual meeting. The polls are now closed. No additional virtual ballots, proxies, or votes, and no changes or revocations will be accepted.
I have been informed by the Inspector of Elections that the preliminary vote report shows that a majority of the votes cast at this meeting have been voted in favor of each of the directors nominated to serve as Class II directors of the company, and that proposals 2 and 3 each received the requisite vote in favor and was therefore approved by our stockholders. We will be reporting the final voting results in a Form 8-K to be filed with the SEC within four business days. This concludes the formal business of today's meeting, and the formal part of this meeting is adjourned.
In closing, I'd like to thank, again, our stockholders in attendance for your participation this morning or this afternoon in our virtual annual meeting and for your interest in Alnylam, the innovative RNAi therapeutics we are commercializing, and the exciting work we are doing to advance our pipeline of investigational RNAi therapeutics for serious diseases. We're grateful for the faith you have placed in us to do our jobs well. We will now take questions from stockholders related to annual meeting matters. Mr. Brodsky, are there any questions from stockholders related to matters properly brought before the meeting?
There are no questions from stockholders related to such matters at this time.
Thank you very much, Mr. Brodsky. The directors, all of whom are present with us this morning, will now direct from the meeting, well, pardon me, will now depart from the meeting. We welcome stockholders to remain online to hear a brief presentation about the company by Mr. Brodsky. Following his presentation, Mr. Brodsky will also be happy to answer any additional pertinent questions submitted online. Have a good day.
Terrific. Thank you very much. Thank you, Ms. Keating, and hello, everyone. My name is Josh Brodsky. I'm Senior Director of Investor Relations and Corporate Communications at Alnylam, and I'm happy to share with you this brief overview of Alnylam. Now, despite the challenges that 2020 presented, we celebrated a lot of exciting milestones and had one of our strongest years ever and have seen this success continue into 2021 as well. We really did embrace our challenge-accepted spirit, and in 2021, Alnylam is poised to begin its transition toward becoming a leading biopharma company. As a reminder, I will be making forward-looking statements during my presentation, and I encourage you to review our most recent SEC filings for a more complete discussion of risk factors. As all of you know, Alnylam is the leading RNAi therapeutics company, having pioneered this as a whole new class of innovative medicines.
We're proud to have led the translation of RNAi from Nobel Prize-winning science into the clinic and ultimately to the commercial markets, where our medicines are indeed having a transformative impact for patients. And while we're now in our 19th year since founding, we're really just in the early innings of realizing the impact of RNAi for human health. Now, at a high level, the key components of Alnylam's business are: first, transformational medicines helping patients around the world with rare and prevalent diseases; second, a robust and high-yield R&D pipeline of first and/or best-in-class product candidates; and third, an organic product engine capable of delivering sustainable innovation. So let's start with a discussion of the transformational medicines that we've brought to market. We're very proud that Alnylam's homegrown innovation has resulted in four globally marketed products in a period of just over two years, a truly remarkable achievement.
ONPATTRO, GIVLAARI, and OXLUMO are wholly owned by Alnylam, and Leqvio, formerly known as inclisiran, is partnered with Novartis, who is leading development and commercialization. These are all transformative medicines for patients with rare and common diseases that are or are expected to be market-leading products for many years to come. As you can see on this slide, we're especially excited about the growth opportunity for our overall commercial profile. In addition to our four currently marketed products, we can expect two additional product launches over the next 12 to 24 months, vutrisiran and fitusiran, which will meaningfully increase the number of revenue-generating Alnylam assets, all of which are in a growth phase for the foreseeable future. We believe this profile of organic growth generation of commercial medicines is nearly unprecedented in biotech history, and we expect to be positioned to expand on this profile in the years to come.
Let's now transition to a discussion of our R&D efforts, where we're advancing Alnylam RNAi innovation for a wide range of rare and common diseases. Alnylam currently has over a dozen programs in active clinical development, spanning phase I to phase IV. While I don't have time to run through all the programs, I do want to highlight our late-stage programs in ATTR amyloidosis, patisiran, and our subcutaneous follow-on vutrisiran, both of which are expected to be significant value drivers for Alnylam in the years to come. You can also appreciate on this slide the substantial product ownership that Alnylam has retained for its pipeline, where we have global or 50/50 rights for the vast majority of programs. Another very important point about Alnylam's R&D efforts is that we have delivered outsized success rates compared with industry norms, creating a high-yielding pipeline.
We believe our success rate underscores the power of an organic, reproducible, and modular platform underpinned by human genetics. Indeed, our track record is now over 60% from IND to positive phase III, compared with industry metrics of less than 10%, a remarkable and, we believe, sustainable difference. I'll now turn briefly to the third key pillar of Alnylam, our organic product engine. This is the source of our sustainable innovation, something rarely seen in a top biotech. Currently, we're advancing over 25 preclinical programs in four tissues: liver, central nervous system, eye, and lung. These programs range from rare to common diseases and are advanced with the aim to be first-in-class and/or best-in-class medicines in the targeted disease indications. The majority of these programs are supported by human genetics.
Alnylam's product engine will deliver two to four new INDs per year, and we aim to achieve four or more INDs per year by the end of 2025. Looking specifically to the CNS, we're very excited about the opportunity for RNAi therapeutics in this area of enormous unmet need, and our first CNS program, ALN-APP, is expected to enter phase I this year. Now, earlier this year, we were thrilled to announce our new five-year vision for our company, Alnylam P5x 25. This vision marks our planned transition to a top five biotech by market cap in the next five years. The five P's of this vision are patients, products, pipeline, performance, and profitability.
The specific goals and metrics are laid out on the bottom of this slide, but to summarize, we aim to become one of the most successful biotech companies ever with transformative medicines in both rare and common diseases for patients around the world, with additional growth through label expansion, a robust and high-yielding pipeline of first and/or best-in-class product candidates from our organic product engine, and impressive financial performance with over 40% revenue CAGR through year-end 2025, and sustainable profitability achieved within this period. Alnylam is now on a clear path toward achieving a self-sustainable financial profile with strong revenue growth and disciplined investment in R&D, with leveraged execution on SG&A. With our current balance sheet of a little under $2 billion and due to our 2020 strategic financing with Blackstone, we believe we're well-positioned to achieve profitability without the need to go to the equity markets.
As you can see, these are exciting times for Alnylam, with a significant transformation expected over the next five years. We are advancing our medicines for rare and common diseases in over four strategic therapeutic areas to help patients around the world. Additionally, we'll leverage our organic product engine as a source of sustainable innovation over the years to come. With Alnylam P5x 25, we believe we're on a path to build a top five biotech in the next five years admired for our culture, scientific innovation, social responsibility, commercial excellence, and first and foremost, a commitment to the patients we serve. Thank you for your time and attention, and we will now turn to any questions that have been submitted.
And I see there was one that was submitted earlier, and the question reads, "Has all the attention and research on mRNA for vaccines resulted in any new opportunities for Alnylam?" So that's an excellent question. I'd say we are delighted that RNA therapies are having a well-deserved moment in the spotlight and that the vaccines are making patients, physicians, and the general public more aware of RNA-based therapeutics and the good that they can do for human health. Now, of course, our focus has always been and continues to be developing RNAi therapeutics and using small interfering RNA to turn off the production of bad-acting proteins rather than messenger RNA or mRNA therapeutics, which essentially provide a blueprint for the body to make wanted proteins. And we're really excited about, and we believe that we have a very rich set of opportunities ahead of us with RNAi therapeutics.
I am not seeing any further questions submitted. In closing, I'd like to thank all of our stockholders participating in this annual meeting for their engagement and their interest in Alnylam and the patients we serve. Thank you, everyone, and have a great day. Bye-bye.